Paper Proffered Program Radiopharmaceuticals, Theranostics, and Nuclear Medicine

Computation Dosimetry of Radioligand Therapy Using Spatial Transcriptomics

Abstract
Purpose

Numerous radioligand therapy (RLT) agents are under various stages of development for treating late-stage cancers. We developed a computational methodology for identifying promising targets for RLT based on spatial transcriptomics analysis of tumor tissue.

Methods

Gene expression maps were captured by digital molecular barcoding on 14 ovarian cancer specimens. Each 2D map represents a 6.5 x 6.5 mm area of tissue, in which the spatial expression profile of 6000 genes is annotated. A second dataset representing gene expression in 3D (19 slices; 10 µm per slice) within a metastatic node was also obtained. Cells within the tissue are categorized by type. Radiation dose distribution is calculated by 2D convolution of radioligand distribution (assumed to mirror target expression) with the dose-point kernel for 177Lu. Injected dose is set to achieve an average dose of 100 Gy in a reference patient. Tumor cell kill is estimated based on a linear radiosensitivity dose response model.

Results

Radiation dose (in units of Gy) was estimated at the level of single cancer cells, allowing for relative comparisons between different patients, injected doses, targets, and radioisotopes. Tumor cell kill >95% was used as a metric to identify promising targets. Mixtures of 2 or 3 ligands were also optimized to maximize response over the entire cohort. Analysis of the 3D dataset, which allowed for more accurate dose calculation, suggest that 2D methods are reasonably accurate.

Conclusion

Spatial transcriptomics data can provide a biological rationale to guide the development of RLT agents. Given the high cost of ligand discovery and drug trials, this computational approach could help narrow down the field of potential candidates, accounting for the microscopic distribution of the molecular target relative to the cancer deposits. It also provides a valuable framework for optimizing combination agent therapy or comparing the efficacy of different radioisotopes.

People

Related

Similar sessions

Poster Poster Program
Jul 19 · 07:00
Adverse Events in Targeted Radionuclide Therapy

Radiopharmaceutical therapy (RPT) plays an important role in the management of oncology patients, particularly those with thyroid cancer, prostate cancer, and neuroendocrine tumor. The use of radionuclide therapy has expanded rap...

Harrison L. Agordzo
Radiopharmaceuticals, Theranostics, and Nuclear Medicine 0 people interested
Poster Poster Program
Jul 19 · 07:00
Development of a Web-Based Theranostic Workflow Management Tool

To develop a Web-Based Theranostic Workflow Management Tool (TWMT) to efficiently manage Theranostic program in the department of radiation oncology (RadOnc).

Ling Zhuang, PhD
Radiopharmaceuticals, Theranostics, and Nuclear Medicine 0 people interested
Poster Poster Program
Jul 19 · 07:00
Epidseg-Net:the Multi-Modal Fusion Framework Based on Drr Guidance In Radiotherapy Is Used for Precise Segmentation of Epid Lung Targets

The proposed multimodal segmentation framework, named EPIDSeg-Net, comprises an encoder, a multi-scale feature layer, and a decoder. The encoder utilizes a dual-branch architecture: a CNN branch for extracting local texture featu...

Huang Qian Qianjia, M.Eng
Radiopharmaceuticals, Theranostics, and Nuclear Medicine 0 people interested